About 

Universe Pharmaceuticals 주식 (NASDAQ: UPC)

에 대한 최신 뉴스 Universe Pharmaceuticals (NASDAQ:UPC) 주식

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

News

Health Care

General

Guardant Health Launches Guardant Hereditary Cancer Test

WIIM

VIPS

Vipshop Holdings shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

New all-in-one IVT kit can deliver up to 2X more mRNA and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=TriLink+BioTechnologies&amp;index=1&amp;md5=d0e424440efc37a9e9b38a277158eddb">TriLink BioTechnologies</a>&reg; (TriLink&reg;), a Maravai&reg; LifeSciences company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), is fueling the future of mRNA research &mdash; starting with a significant donation to top academic labs across the U.S. and Europe.
The donation commemorates the launch of TriLink&#39;s first&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftrilinkbiotech.com%2Fcleancap-ivt-kits&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=mRNA+synthesis+kit&amp;index=2&amp;md5=10cb95d3eb0cfb8f9c96258074fbfeac">mRNA synthesis kit</a>&nbsp;featuring CleanCap&reg; capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each that can yield up to a combined 250mg of capped mRNAs, enabling and encouraging further discovery and development in the field of mRNA-based medicine.
Labs in academic institutions, such as those listed below, have gratefully accepted the kits donated by TriLink to drive progress in RNA therapeutics and build a strong future for the field.
<ul>
<li>The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI)</li>
<li>The Center of RNA Technologies and Therapeutics at UC San Diego</li>
<li>The University Medical Center Utrecht</li>
<li>The University of Oxford</li>
<li>Yale School of Medicine</li>
</ul>
The new&nbsp;in vitro&nbsp;transcription (IVT) kit will simplify mRNA synthesis and elevate IVT by leveraging TriLink&#39;s high-performing products where users can expect up to 2X more mRNA yield and up to&nbsp;85%&nbsp;lower dsRNA compared to other kits on the market. The IVT kit components include:
<ul>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleancap-reagent-ag-3-ome.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanCap%26%23174%3B+AG+%283%26%238242%3B+OMe%29&amp;index=3&amp;md5=b347179ae00eb2c566bb7ffc698a0def">CleanCap&reg; AG (3&prime; OMe)</a>&nbsp;for co-transcriptional capping</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fcleanscribe-rna-polymerase.html&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScribe%26%238482%3B+RNA+Polymerase&amp;index=4&amp;md5=10f50085c672dd825897927874d4807c">CleanScribe&trade; RNA Polymerase</a>&nbsp;for dsRNA reduction</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2Fbrowse%2Fnucleoside-triphosphates-nucleotides&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=Nucleotides+including+N1-methylpseuouridine&amp;index=5&amp;md5=6d9fb4fe33940c3648a6d1443b2a762a">Nucleotides including N1-methylpseuouridine</a>&nbsp;for enhanced mRNA performance, and</li>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgo.trilinkbiotech.com%2Fcleanscript-technote&amp;esheet=54257039&amp;newsitemid=20250520267814&amp;lan=en-US&amp;anchor=CleanScript%26%23174%3B+IVT&amp;index=6&amp;md5=4f9c217670825905028a1a55813f06d4">CleanScript&reg; IVT</a>&nbsp;for increased yield.</li>
</ul>
&quot;This launch brings together a powerful suite of novel IVT components that reflect TriLink&#39;s years of experience and innovation in mRNA synthesis,&quot; shared Justin Barbosa, Vice President &amp; General Manager of TriLink Discovery. &quot;By offering all these components in a single kit, we&#39;re simplifying researcher workflow and accelerating discovery. The addition of CleanScript IVT optimization also ensures our customers can generate more high-quality mRNA per reaction &mdash; maximizing both efficiency and performance.&quot;
The kit comes ready to use and is the only commercially available IVT kit featuring CleanCap AG (3&prime; OMe), which is a modified version of the original CleanCap AG with over&nbsp;95%&nbsp;capping efficiency to improve protein expression. CleanCap co-transcriptional capping provides advantages over legacy capping methods of ARCA or enzymatic by streamlining mRNA manufacturing with fewer steps and handling, thereby saving researchers time and resources.
&quot;This is an important product launch, where we are bringing several technology and process improvements to an integrated IVT kit,&quot; said Trey Martin, CEO of Maravai. &quot;Today we are also making a statement about our commitment to the future of mRNA science. By donating the first new kits to top academic institutions across the U.S. and Europe, we are investing in the next generation of mRNA innovators and empowering groundbreaking research that could lead to the therapies of tomorrow. We are honored to help our field continue to evolve and improve through new innovations and process improvements.&quot;

MRVI

Trilink Biotechnologies Releases Its First mRNA Synthesis Kit With CleanCap Capping Technology

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity
- Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026
- Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, provides an overview of the clinical development program for its highly-differentiated antibody-drug conjugate (ADC), ALX2004, at the Company's R&amp;D webcast event today. ALX Oncology leadership will discuss the unique design profile, preclinical data and clinical development plans for ALX2004, a potential best- and first-in-class ADC for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors, that is planned to enter Phase 1 studies in mid-year 2025.

Biotech

ALXO

ALX Oncology Unveils Clinical Development Plans For ALX2004, A ADC Targeting EGFR-Expressing Tumors, With Phase 1 Trials Set For Mid-2025 Following FDA IND Clearance And Initial Data Expected In 1H 2026, While Advancing CD47-Blocker Evorpacept In Breast And Colorectal Cancer Trials Also Starting Mid-2025

QBTS

D-Wave Quantum shares are trading higher after the company announced it launched its Advantage2 quantum system to address problems in optimization, AI, and materials simulation.

Management

DUOT

Duos Technologies Appoints Craig Nixon As Board Chairman

Enveric files provisional patent application on newly identified group of molecules
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enveric.com%2F&amp;esheet=54257417&amp;newsitemid=20250520560158&amp;lan=en-US&amp;anchor=Enveric+Biosciences&amp;index=1&amp;md5=37b64f3d388bee9bd58bcc72888a61c7">Enveric Biosciences</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confirmed through further testing, the potential of this newly identified group of molecules expands the market potential for Enveric drug candidates in a new direction.
Neurodegenerative diseases are a heterogenous group of progressive neurological disorders characterized by the gradual loss of neurons, leading to a decline in cognitive, motor and other neurological functions. It has been estimated by the World Health Organization (WHO) that approximately 50 million people worldwide are affected by neurodegenerative diseases, with seven million in the United States.
Broad claims in the patent application describe a group of molecules that enhance brain derived neurotrophic factor ("BDNF") activity and address conditions where the BDNF/TrKB pathway plays a major role. BDNF and its receptor TrKB support neuroprotection and adult neurogenesis and enhance myelination by increasing the density of oligodendrocyte progenitor cells. While additional pre-clinical testing is needed to confirm the enhancement of BDNF activation, preliminary studies have revealed promotion of neuronal development in a cell-based assay.
The preliminary PK profile suggests that the orally delivered compound effectively enters the bloodstream, penetrates the brain, and is subsequently and rapidly cleared from plasma. Further, this molecule did not display 5HT2B receptor activation, which would have been an indicator of cardiovascular risk potential.

ENVB

Enveric Biosciences Files New Provisional Patent Application With Claims To Methods, Pharmaceutical Formulations For Use On Family Of Molecules Discovered To Offer Potential To Address Neurodegenerative Disease

Guidance

TRNR

Interactive Strength Updates Investor Presentation To Reflect Over $20M In Pro Forma Revenue And 15% Increase In 2025 Pro Forma Revenue Guidance To $75M+

Barclays analyst Matthew Bouley maintains Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) with a Equal-Weight and raises the price target from $6 to $11.

Price Target

Analyst Ratings

LSEA

Barclays Maintains Equal-Weight on Landsea Homes, Raises Price Target to $11

NextPlat Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>, NXPLW)), NXPLW) (&quot;NextPlat&quot; or the &quot;Company&quot;), a global e-Commerce provider, today announced that its subsidiary,&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431226-1&amp;h=3979826504&amp;u=https%3A%2F%2Fgtc.co.uk%2F&amp;a=Global+Telesat+Communications+Ltd" target="_blank">Global Telesat Communications Ltd</a>&nbsp;(&quot;GTC&quot;) has been named the exclusive UK and European Economic Area distributor for<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4431226-1&amp;h=841107999&amp;u=https%3A%2F%2Fwww.zoleo.com%2Fen-us&amp;a=+ZOLEO+Inc.+(%22ZOLEO%22)%2C+an+innovative+brand+leader+in+the+satellite+communicator+segment" target="_blank">&nbsp;ZOLEO Inc. (&quot;ZOLEO&quot;), an innovative brand leader in the satellite communicator segment</a>.
ZOLEO&#39;s flagship product, the award-winning ZOLEO global satellite communicator, extends smartphone messaging coverage worldwide by utilizing the Iridium&reg;&nbsp;satellite network, cellular, and Wi-Fi networks. This device enables users to send and receive messages, access weather forecasts, and trigger SOS alerts with 24/7 monitoring, making it particularly valuable for outdoor enthusiasts, remote workers, and travelers. Notably, ZOLEO has received several industry accolades, including being named as the Outdoor Retailer Innovation Award &quot;Product of the Year.&quot; ZOLEO satellite communicators complement GTC&#39;s growing portfolio of satellite connectivity products currently sold globally via its e-commerce and Amazon storefronts.

Contracts

NXPL

NextPlat's Global Telesat Named Exclusive UK And EU Distributor For ZOLEO Satellite Communicators

Barclays analyst Paul Kearney maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Overweight and raises the price target from $75 to $86.

Barclays Maintains Overweight on Kontoor Brands, Raises Price Target to $86

<h3>Gainers</h3>
<ul>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares rose 155.4% to $0.26 during Tuesday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) stock rose 8.34% to $13.38. The company's market cap stands at $469.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock moved upwards by 7.33% to $0.64. The company's market cap stands at $16.7 million. </li>
<li>NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) shares increased by 6.01% to $0.64. The company's market cap stands at $16.4 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Gaxos.AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) stock moved upwards by 5.87% to $1.31. The company's market cap stands at $9.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares increased by 5.84% to $3.08. The company's market cap stands at $62.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) shares declined by 9.1% to $7.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Token Cat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) stock decreased by 7.64% to $0.71. The market value of their outstanding shares is at $2.2 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares declined by 5.27% to $1.26. The company's market cap stands at $21.6 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares fell 4.54% to $0.58. The company's market cap stands at $5.7 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock declined by 4.46% to $2.36. The market value of their outstanding shares is at $3.6 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) stock fell 4.3% to $0.76. The market value of their outstanding shares is at $7.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BAOS

BLMZ

GAMB

GXAI

MITQ

QMMM

SURG

TNMG

VSME

YALA

12 Communication Services Stocks Moving In Tuesday's Pre-Market Session

JFB Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>) reported $5.91 million in sales this quarter. This is a 136.52 percent increase over sales of $2.50 million the same period last year.

Earnings

JFB Construction Q1 Sales $5.91M Up From $2.50M YoY

CureVac reaffirmed expected cash runway into 2028,

Earnings Misses

CVAC

CureVac Q1 Sales $946.45K Miss $3.34M Estimate, Company Exits Quarter With Cash And Equivalents Worth $460.91M

<h3>Gainers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 56.6% to $1.77 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares increased by 30.17% to $22.0. The company's market cap stands at $144.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 27.47% to $0.01. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock moved upwards by 25.23% to $1.34. The market value of their outstanding shares is at $22.2 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 24.84% to $0.28. The market value of their outstanding shares is at $5.1 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 14.48% to $403.0. The company's market cap stands at $5.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 20.7% to $8.8 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 19.6% to $0.33. The company's market cap stands at $1.5 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock decreased by 18.16% to $0.27. The company's market cap stands at $7.8 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock decreased by 13.1% to $0.09. The company's market cap stands at $6.1 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock decreased by 11.03% to $1.21. The company's market cap stands at $6.9 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 10.45% to $0.3. The market value of their outstanding shares is at $1.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

BIAF

EKSO

ENTO

EYEN

HCTI

IRIX

LYRA

PSTV

PTIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>JFB Construction (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFB#NASDAQ">JFB</a>) stock increased by 18.5% to $6.03 during Tuesday's pre-market session. The company's market cap stands at $55.7 million. </li>
<li>Micropolis Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MCRP#AMEX">MCRP</a>) shares moved upwards by 16.34% to $2.42. The market value of their outstanding shares is at $84.4 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) shares rose 15.11% to $4.95. The market value of their outstanding shares is at $124.6 million. </li>
<li>Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) shares increased by 11.49% to $1.65. The company's market cap stands at $50.7 million. </li>
<li>GEE Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/JOB#AMEX">JOB</a>) shares moved upwards by 10.7% to $0.21. The market value of their outstanding shares is at $22.9 million. As per the press release, Q2 earnings came out 4 days ago. </li>
<li>Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares rose 7.02% to $6.25. The company's market cap stands at $43.1 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) stock fell 8.2% to $1.79 during Tuesday's pre-market session. The market value of their outstanding shares is at $132.0 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares decreased by 7.87% to $0.47. The company's market cap stands at $14.7 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock fell 7.76% to $1.19. The market value of their outstanding shares is at $13.0 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock fell 7.19% to $0.3. The company's market cap stands at $42.9 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares decreased by 4.45% to $4.51. The market value of their outstanding shares is at $753.9 million. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares fell 4.32% to $6.65. The company's market cap stands at $332.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELPW

FTEK

HKPD

KSCP

MCRP

SCWO

SHLS

SPWR

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares increased by 12.9% to $14.85 during Tuesday's pre-market session. The company's market cap stands at $4.3 billion. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock moved upwards by 10.64% to $3.43. The company's market cap stands at $397.9 million. </li>
<li>CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) stock increased by 8.29% to $1.41. The market value of their outstanding shares is at $27.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares moved upwards by 7.18% to $12.68. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) shares moved upwards by 6.89% to $5.74. The market value of their outstanding shares is at $182.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) stock increased by 6.82% to $105.16. The company's market cap stands at $8.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock fell 14.9% to $2.0 during Tuesday's pre-market session. The company's market cap stands at $51.6 million. </li>
<li>Lianhe Sowell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) shares decreased by 8.01% to $1.15. The market value of their outstanding shares is at $59.7 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares decreased by 7.0% to $0.22. The company's market cap stands at $14.3 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares fell 6.04% to $0.47. The market value of their outstanding shares is at $17.6 million. As per the press release, Q2 earnings came out 4 days ago. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares declined by 5.84% to $1.13. The company's market cap stands at $6.9 million. </li>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) stock declined by 5.41% to $7.0. The company's market cap stands at $7.7 million. As per the press release, Q2 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AISP

CXAI

FORD

LAES

LDTC

LHSW

PEGA

QUBT

SGMA

TDTH

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Viking Holdings shares are trading lower following Q1 reported financial results.

Barclays analyst Theresa Chen maintains Kinetik Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNTK#NYSE">KNTK</a>) with a Equal-Weight and lowers the price target from $58 to $48.

KNTK

Barclays Maintains Equal-Weight on Kinetik Holdings, Lowers Price Target to $48

Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) will release its third-quarter earnings results after the <a href="https://www.benzinga.com/quote/PANW/earnings">closing bell on Tuesday, May 20.</a>
Analysts expect the Santa Clara, California-based company to report quarterly earnings at 77 cents per share. That's up from 66 cents per share in the year-ago period. According to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, Palo Alto Networks projects to report quarterly revenue at $2.28 billion, compared to $1.98 billion a year earlier.
On April 28, Palo Alto Networks entered into a definitive agreement to acquire Protect AI.
Palo Alto Networks shares gained 0.7% to close at $194.30 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Cantor Fitzgerald analyst Jonathan Ruykhaver reiterated an Overweight rating with a price target of $223 on May 19, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Jefferies analyst Joseph Gallo maintained a Buy rating and raised the price target from $215 to $225 on May 16, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Roth Capital analyst Taz Koujalgi initiated coverage on the stock with a Neutral rating and a price target of $210 on May 15, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Morgan Stanley analyst Hamza Fodderwala maintained an Overweight rating and slashed the price target from $230 to $205 on April 16, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Stephens &amp; Co. analyst Todd Weller initiated coverage on the stock with an Equal-Weight rating and a price target of $205 on April 1, 2025. This analyst has an accuracy rate of 68%</li>
</ul>
Considering buying PANW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20033653/image-234-1024x626.png" alt="" class="wp-image-920809" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20033653/image-234-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20033653/image-234-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20033653/image-234-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/20033653/image-234.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45492092/jim-cramer-was-skeptical-of-rocket-lab-now-says-its-actually-a-decent-story">Jim Cramer Was &#8216;Skeptical&#8217; Of Rocket Lab, Now Says &#8216;It&#8217;s Actually A Decent Story&#8217;</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

PANW

Palo Alto Networks Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Press Releases

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Universe Pharmaceuticals INC Announces Share Consolidation

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering

Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

Comments

Universe Pharmaceuticals

뉴스

에 대한 최신 뉴스 Universe Pharmaceuticals (NASDAQ:UPC) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌